Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 189 for “"Triple-negative breast cancer"”.
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
Basal-like breast cancers are generally negative for estrogen and progesterone receptor expression and HER-2 amplification (‘triple negative’ breast cancer, TNBC), and express basal cytokeratins 5/6, and EGFR (epidermal growth factor receptor). No targeted therapy options are currently approved for …
-
Mechanism of metastasis of triple negative breast cancer
Triple Negative Breast Cancer (TNBC) is increasingly recognised as a serious, worldwide public health concern. TNBC has the ability to recur after treatment and appears to be greatest in the first few years. The phenotypical changes of the TNBC metastasis represent a unique that heterogeneous …
-
Engineering multimodal nanoparticles to combat triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of cancer that accounts for about 15-20% of all breast cancer cases and has a poorer short-term prognosis when compared to other subtypes. Many current chemotherapeutics used to treat TNBC are nonspecific, and, therefore, cause …
-
Engineering therapeutic messenger RNA for triple-negative breast cancer
… therapies are revolutionising the landscape of cancer treatment, providing better therapeutic responses and minimising the adverse effects of conventional treatments such as radiation and chemotherapy. Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancer types and …
-
NANOPARTICLE BASED MULTI-MODAL THERAPIES AGAINST TRIPLE-NEGATIVE BREAST CANCER
Triple-negative breast cancer (TNBC) is a highly metastatic and lethal form of breast cancer that lacks surface markers commonly targeted by hormone or immunotherapies. Silver nanoparticles (AgNPs) have exhibited a selective toxicity against TNBC cell lines at concentrations that are not lethal to …
-
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
Breast cancer is the most common form of female malignancy globally. There are several subtypes of breast cancers including Triple-negative breast cancer (TNBC), which is mainly characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal …
-
A Screen For Peptides Targeting Chemoresistant Metastatic Triple-Negative Breast Cancer
<p>Cancer metastasis is the principal cause of most cancer-associated morbidities. While radiotherapy, hormone therapy, and novel therapeutic strategies, including immunotherapy, have shown promise in inhibiting tumor growth, chemotherapy remains the mainstay in the clinical management of …
-
Identifying Oncogenic Drivers of Poor Outcome in Triple Negative Breast Cancer
Triple Negative Breast cancers (TNBC) are defined by an absence of HER2 amplification, and a lack of estrogen (ER) and progesterone (PR) expression. They are an especially aggressive and poor prognosis subtype of Breast cancer and are associated with high incidence of chemoresistance and …
-
Investigating the transcriptional regulation of BCL11A in Triple-negative Breast Cancer
Breast cancer is the most common type of cancer in women worldwide. It can be classified into several subtypes based on the histological expression of Estrogen, Progesterone and HER-2 receptors. The most aggressive subtype of breast cancer is called Triple-negative breast cancer (TNBC) and is …
-
Astaxanthin Decreases Invasion and MMP Activity in Triple Negative Breast Cancer Cells
… was effective against invasion and metastasis of triple-negative breast cancer (TNBC) cells. We determined that Astaxanthin decreases invasion of 4T1 cells through Matrigel<sup>TM</sup>, but does not affect proliferation. Using zymography we showed that 4T1 cells treated with Astaxanthin …
-
Mir-484 Functions As An Onco-Mir In Triple Negative Breast Cancer
<p>Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major …
-
Identification of novel biomarkers and therapeutic strategies in triple negative breast cancer
Triple negative breast cancer (TNBC) is a highly heterogeneous disease that accounts for around 15% of all breast cancers but is responsible for a disproportionately high rate of mortality. Characterised by lack of expression of the hormone receptors estrogen receptor α (ERα), progesterone receptor …
-
Development of Novel Peptide-Doxorubicin Conjugates for Targeting Triple-Negative Breast Cancer
<p>Triple-negative breast cancer (TNBC) is the most aggressive and difficult to treat subtype of breast cancer. Chemotherapy is an active treatment option in combination with other treatments; however, the side effects limit the effective therapeutic dose. To selectively target the cancer cells, I …
-
Investigation of anthracycline based topoisomerase II inhibitors in triple negative breast cancer
Triple negative breast cancer (TNBC) constitutes10-20% of all breast cancer (BCa) cases. TNBC remains unresponsive to targeted therapy, and primarily relies on chemotherapy for treatment. Mitoxantrone (MTX), a topoisomerase II inhibitor belonging to the anthracenedione class, is used in BCa …
-
Evaluating CD44-EZRIN Interactions in Triple-Negative Breast Cancer: Tumourigenesis and Drug Resistance
When breast cancer is detected at an early localized stage, surgery is often successful in achieving long term survival. However, when breast cancer becomes invasive and progresses to metastatic disease, surgery followed by adjuvant therapies is required, and many patients fail to respond or …
-
SMYD3: A PLAYER IN STEMNESS AND CHROMOSOME INSTABILITY IN TRIPLE NEGATIVE BREAST CANCER
… di SMYD3 nel pathway di cGAS-STING. Le cellule cancerose sono caratterizzate da un alto livello di CIN, il quale porta al rilascio di DNA genomico nel citoplasma, che viene riconosciuto dal pathway di cGAS-STING, che viene a sua volta attivato nel suo ramo pro-sopravvivenza. Questo porta …
-
Combating Resistance To Epidermal Growth Factor Recpetor Inhibitors In Triple Negative Breast Cancer
<p>Triple negative breast cancer (TNBC) patients suffer from a highly malignant and aggressive cancer that lacks an effective targeted therapeutic. Although many TNBCs, both in vitro and in vivo, have increased expression of epidermal growth factor receptor (EGFR), EGFR targeted inhibitors, such as …
Page 1 of 10